Lysis of endothelial cells by autologous lymphokine-activated killer cells (original) (raw)

Access this article

Log in via an institution

Subscribe and save

• Starting from 10 chapters or articles per month
• Access and download chapters and articles from more than 300k books and 2,500 journals
• Cancel anytime View plans

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

1. Muul JJ, Shu S, Schwartz SL, Rosenberg SA (1984) Adoptive immunotherapy of established pulmonary metastasis with LAK cells and recombinant IL2. Science 225: 1487
   PubMed Google Scholar
2. Lafreniere R, Rosenberg SA (1985) Adoptive immunotherapy of murine hepatic metastasis with LAK cells and recombinant IL-2 can mediate the regression of both immunogenic and nonimmunogenic sarcomas and adenosarcoma. J Immunol 135: 4273
   PubMed Google Scholar
3. Rosenberg SA, Lotze MT, Muul LM (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316: 889
   PubMed Google Scholar
4. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WN, Seipp CA, White DE (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210: 474
   PubMed Google Scholar
5. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA (1986) High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: responses, treatment-related morbidity, and histologic findings. JAMA 256: 3117
   PubMed Google Scholar
6. Lotze MT, Matory YL, Rayner AA Etinghausen SE, Seipp CA, Rosenberg SA (1986) Clinical effects and toxicity of IL-2 in patients with cancer, Cancer 58: 2764
   PubMed Google Scholar
7. Rosenstein M, Ettinghausen SE, Rosenberg SA (1986) Extravasation of intracellular fluid mediated by the systemic administration of recombinant IL-2. J Immunol 137: 1735
   PubMed Google Scholar
8. Damle NK, Doyle LV, Bender JR, Bradley EC (1987) Interleukin activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and caused their lysis. J Immunol 138: 1779–1785
   PubMed Google Scholar
9. Miltenburg AMM, Meijer-Paape ME, Daha MR, Paul LC (1987) Endothelial cell lysis by lymphokine activated human peripheral mononuclear cells. Eur J Immunol 17: 1383–1386
   PubMed Google Scholar
10. Kotasek D, Vercellotti GM, Ochoa AC, Bach FH, White JG, Jacob HS (1988) Mechanism of cultured endothelial injury by lymphokine-activated killer cells. Cancer Res 48: 5528–5532
    PubMed Google Scholar
11. Mier JM, Brandon EP, Libby P, Janicka MW, Aronson FR (1988) Activated endothelial cells resist lymphokine-activated killer cellmediated injury. Possible role of induced cytokines in limited capillary leak during IL-2 therapy. J Immunol 143: 2407–2414
    Google Scholar
12. Renkonen R, Ristimaki A, Hayry P(1988) Interferon-gamma protects human endothelial cells from lymphokine-activated killer-mediated lysis. Eur J Immunol 18: 1839
    PubMed Google Scholar
13. Fujita S, Puri RK, Yu ZX, Travis WD, Ferrans VJ (1991) An ultrastructural study of in vivo interactions between lymphocytes and endothelial cells in pathogenesis of vascular leak syndrome induced by interleukin-2. Cancer 68: 2169
    PubMed Google Scholar
14. Imamura T, Mitsui Y (1987) Heparan sulfate and heparin as a potentiator or a suppresser of growth of normal and transformed vascular endothelial cells. Exp Cell Res 172: 92
    PubMed Google Scholar
15. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral lymphocytes. J Exp Med 155: 1823
    PubMed Google Scholar
16. Rosenstein M, Yron I, Kaufmann Y, Rosenberg SA (1984) Lymphokine-activated killer cells: lysis of fresh natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. Cancer Res 44: 1946
    PubMed Google Scholar
17. Carl M, Dasch DA (1986) Characterization of human cytotoxic lymphocytes directed against cells infected with typhus group rickettsiae: evidence for lymphokine activation of effectors. J Immunol 136: 245
    Google Scholar
18. Sabouste CS, Dawson L, Remington JS (1992) Human lymphokine-activated killer cells are cytotoxic against cells infected with_Toxoplasma gondii_. J Exp Med 176: 1511
    PubMed Google Scholar
19. Phillips JH, and Lanier LL (1986) Dissection of lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 164: 814
    PubMed Google Scholar
20. Tilden AB, Itoh K, Balch CM (1987) Human lymphokine activated killer cells: identification of two types of effector cells. J Immunol 138: 1068
    PubMed Google Scholar
21. Ballas ZK, Rasmussen W, Van Otengam JK (1987) Lymphokine activated killer (LAK) cells. II. Delineation of distinet murine LAK-precusor subpopulations. J Immuno 138: 1647
    Google Scholar
22. Ballas ZK, Rasmussen W (1990) Lymphokine activated killer (LAK) cells. IV. Characterization of murine effector subpopulations. J Immunol 144: 386
    PubMed Google Scholar
23. Sasaki A, Melder RJ, Whiteside TL, Herberman RB, Jain RK (1991) Pieferential localization of human adherent LAK cells in tumor microcirculation. J Natl Cancer Inst 83: 443
    Google Scholar
24. Chong AS, Boussy IA, Graf LH, Scuderi P (1992) Stimulation of IFN gamma. TNF-alpha, and TNF-beta secretionin IL-2 activated T cells: costimulatory roles for LFA-1, LFA-2, CD44, and CD45 molecules. Cell Immunol 144: 69
    PubMed Google Scholar
25. Chong AS, Boussy IA, Graf LH, Scuderi P (1992) Monoclonal antibodies anti-CD3, anti-TCR alpha beta and anti-CD2 act synergistically with tumor cells to stimulate lymphokine activated killer cells and tumor-infiltrating lymphocytes to secrete interferon gamma. Cancer Immunol Immunother 35: 335
    PubMed Google Scholar
26. Cotran RS, Pober JS, Gimbrone MA, Springer TA, Wiebke EA, Gaspari AA, Rosenberg SA, Lotze MT (1987) Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome. J Immunol 139: 1883
    Google Scholar
27. Quillet A, Presse F, Marchiol-Fournigault C, Harel-Bellan A, Benbunan M, Ploegh H, Fradelizi D (1988) Increased resistance to non-MHC-restricted cytotoxicity related to HLA A, B, expression. J Immunol 141: 17
    PubMed Google Scholar
28. Karlhofer FM, Ribaudo RK, Yokoyama WM (1992) MHC class I alloantigen specificity of Ly-49+ IL-2 activated natural killer cells. Nature 358: 66
    PubMed Google Scholar
29. Ljunggren HG, Karre K (1990) In search of the “missing self”: MHC molecules and NK cell recognition. Immunol Today 11: 237
    PubMed Google Scholar
30. Folkman J, Watson K, Ingber D, Hanahan D (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58–61
    PubMed Google Scholar
31. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent. J Natl Cancer Inst 82: 4–6
    PubMed Google Scholar

Download references